KRAS Primer Design

About KRAS

The KRAS gene (Kirsten rat sarcoma viral oncogene homolog) on chromosome 12p12.1 encodes a small GTPase that transduces signals from growth factor receptors. KRAS mutations, particularly in codons 12, 13, and 61, are among the most common oncogenic drivers in pancreatic, colorectal, and lung cancers. KRAS spans ~45 kb with 6 coding exons.

NCBI Gene ID: 3845 | RefSeq: NM_004985.5 | Genomic: NC_000012.12 (25205246-25250930)

KRAS Primer Design Challenges

• Hotspot codons 12 & 13: Exon 2 contains the most frequently mutated residues (G12C, G12D, G12V, G13D), requiring precise amplicon targeting
• GC-rich exon 2: Over 65% GC content around codons 12–13, requiring adjusted PCR parameters
• Pseudogenes: KRASP1 pseudogene shares high sequence homology with exons 4–6, risking non-specific amplification
• Small gene size: Only 6 exons with short introns limit primer placement options
• Low tumor content: Liquid biopsy applications require high sensitivity primers for detecting low-frequency mutations

Recommended Primer Design Parameters for KRAS

Key SNPs to Avoid in Primer Binding Sites

When designing KRAS primers, avoid these clinically significant variants:

• rs121913530 (c.34G>T, G12C) — Most common KRAS mutation in NSCLC
• rs121913529 (c.35G>A, G12D) — Frequent in pancreatic cancer
• rs112445441 (c.38G>A, G13D) — Exon 2 codon 13 variant
• rs121913535 (c.37G>T, G13C) — Exon 2 codon 13 variant
• rs121913240 (c.182A>T, Q61L) — Exon 3 codon 61 mutation

Recommended Primer Sequences for KRAS — Engine-Designed on NM_004985.5

The three pairs below were produced by VigyanLLM's automatic primer design engine directly against the Homo sapiens KRAS RefSeq mRNA NM_004985.5 (5306 nt), under the engine's default constraints: 18–25 nt primers, Tm 57–72 °C (optimum 62 °C), GC 40–60%, and an 80–1500 bp amplicon (optimum 150 bp). Every oligo was then re-checked back against the accession — each forward primer matches the sense strand at its stated 1-based position and each reverse primer matches the reverse complement ending at the amplicon's final base (3 of 3 exact matches for this page).

Pair 1 leads with a forward/reverse Tm spread of 0.0 °C, no stable hairpin at 37 °C (ΔG ≥ -0.7 kcal·mol⁻¹ on either oligo), self-dimer Tm at most 6.5 °C, no cross-dimer signal, no pair warnings, and a Primer3 pair-quality score of 100.0/100; the suggested starting annealing temperature is 53.9 °C. Pairs 2 and 3 are alternates from the same run — compare their Tm, GC and product columns above against your chemistry (dye-based or probe), then confirm every candidate in silico and on a gel before use.

How to read this table: these are default whole-transcript designs — they demonstrate what the engine produces under standard constraints and are not positioned over the clinically relevant variants discussed below; to land an amplicon on a specific codon or repeat, design against that region deliberately. Thermodynamics come from Primer3's nearest-neighbor engine (SantaLucia 1998). Example output only: validate each candidate experimentally (gel sizing, efficiency series, melt-curve or probe check) before relying on it.

Design Guidance for KRAS Assays

KRAS encodes a small GTPase that cycles between active GTP-bound and inactive GDP-bound states and relays growth-factor signals from EGFR through the RAS–MAPK pathway. Human cells express two major isoforms, KRAS4A and KRAS4B, produced by alternative splicing of the final coding exons; they differ only at the C-terminus, so primers in the shared upstream coding exons measure both isoforms, while primers spanning the isoform-specific final exons can separate them.

Oncogenic missense variants concentrate in codons 12, 13 and 61 (listed above), locking the protein in the GTP-bound state. Two consequences for primer design: for sequencing-based genotyping, centre the codon of interest in the amplicon and keep both primers in variant-free flanks so no allele is dropout-prone — whereas allele-specific (ARMS-style) detection deliberately places the discriminating base at the 3′ terminus of an allele-specific primer. KRAS also has a processed pseudogene, KRAS1P, with extensive homology to the coding region, so for genomic-DNA templates an in-silico specificity check is not optional. FFPE tumour DNA fragments badly; keep amplicons short (≤150 bp — the example pair above is 144 bp).

Before you order: re-check both binding sites against dbSNP and gnomAD — a common variant under one primer causes allele dropout and mysterious assay failures — confirm specificity in silico for the template you will actually use, run an annealing gradient around 53.9 °C (the engine's starting suggestion for pair 1), verify a single band of the expected size on a gel, and record primer sequence, lot and efficiency with the run as MIQE requires.

References

• NCBI Nucleotide — RefSeq NM_004985.5 (Homo sapiens KRAS mRNA).
• NCBI Gene — KRAS (Homo sapiens).
• SantaLucia J Jr. A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. Proc Natl Acad Sci USA 1998;95:1460–1465.
• Untergasser A, Cutcutache I, Koressaar T, et al. Primer3—new capabilities and interfaces. Nucleic Acids Res 2012;40:W115–W118.
• Ye J, Coulouris G, Zaretskaya I, et al. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. Nucleic Acids Res 2009.
• Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611–622.